Akeso Approved for China Trial of Dual PD-1 Bi-Specifics Therapy
publication date: Jan 7, 2022
Akeso, a Hangzhou biopharma, was approved to start a China Phase Ib/II trial of a dual PD-1-based bi-specific therapy for advanced non-small cell lung cancer (NSCLC). The therapy will combine cadonilimab (PD-1/CTLA-4 bi-specific antibody), a first-in-class novel immunotherapy developed by Akeso, with ivonescimab (PD-1/VEGF bi-specific antibody), another Akeso candidate. Akeso said the trial is the world's first study of two combined bi-specific antibodies. Cadonilimab is already under review in China as a second-line therapy for cervical cancer. More details....
Stock Symbol: (HK: 09926)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.